United States: First Circuit Rejects Whistleblower's Fraud On The FDA FCA Theory

On December 23, 2016, the First Circuit held that a relator under the federal False Claims Act (“FCA”) failed to plausibly plead that defendant medical device manufacturers caused the submission of false claims for reimbursement by fraudulently obtaining Food and Drug Administration approval (“FDA”) for a medical device. Citing the fact that FDA had not withdrawn its approval of the device in the years since relator filed his qui tam suit, the panel in D’Agostino v. ev3, Inc., No. 16-1126, 2016 WL 7422943 (1st Cir. Dec. 23, 2016) held that relator failed to plead a causal connection between the alleged misrepresentations to FDA during the device approval process and the government’s subsequent payment of claims involving the device. For this and other reasons discussed below, the panel affirmed the district court’s ruling that further amendments to the complaint would be futile.

Background

Relator Jeffrey D’Agostino, a former sales representative for defendants ev3 and MTI, first filed suit in October 2010 in the United States District Court for the District of Massachusetts. Over the course of several years, relator amended his complaint three times. After the government declined to intervene in the case, the case was unsealed, and defendants moved to dismiss.

Relator responded to the motions to dismiss by filing a fourth amended complaint without seeking leave of the court. The district court construed this filing as a motion to amend and denied it under Fed. R. Civ. P. 16(b)’s “good cause” standard. Subsequently, after briefing and argument on the motions to dismiss, the district court dismissed the then-operative version of the complaint. Relator appealed, and the First Circuit reversed and remanded in United States ex rel. D’Agostino v. ev3 Inc., 802 F.3d 188 (1st Cir. 2015), holding that the district court should have evaluated relator’s request for leave to amend under Rule 15(a)’s more lenient standard instead of Rule 16(b).

On remand, relator moved to amend and proffered yet another amended complaint. Relator alleged that defendants caused the submission of false claims for Onyx and Axium, two medical devices used to treat brain abnormalities through minimally invasive endovascular procedures. Relator’s principal theory regarding Onyx was that MTI had defrauded the FDA during the premarket approval process by allegedly overstating the planned extent of its physician training program, denying that it intended to promote the device for off-label uses, and concealing the link between Onyx and another device that was ultimately recalled for safety reasons. Relator asserted that but for this supposed fraud, FDA would not have approved Onyx. Government health care programs generally only pay for devices that have been approved or cleared by FDA, so relator argued that every claim for an Onyx procedure was false under the FCA.

In addition to alleging that every Onyx claim was false due to this supposed fraud on the FDA, relator also alleged that Onyx claims submitted by physicians who had not attended defendants’ training programs were false, under the theory that use by untrained physicians was not medically reasonable or necessary. Finally, Relator alleged that every claim for Axium was false because the device was defectively designed and defectively manufactured.

The First Circuit’s Holding

A unanimous panel of the First Circuit agreed with the district court that relator’s proposed amended complaint was futile. Devoting the bulk of its analysis to relator’s “fraud on the FDA” theory, the First Circuit held that if the FDA has not withdrawn its approval from a device or taken another official action confirming that it was defrauded, then a relator cannot base an FCA claim on the theory that FDA approval was fraudulently obtained. The panel noted that FDA does not itself pay claims for medical devices. Rather, such claims are paid by federal healthcare programs such as the Centers for Medicare and Medicaid (“CMS”) services, on the condition (with some exceptions) that the devices involved were approved or cleared for marketing by FDA. Because the supposed fraud was directed to FDA rather than CMS, the panel reasoned that if FDA was not, in fact, defrauded, then defendants could not have caused the submission of false claims to CMS as a matter of law.

The panel was notably alert to the practical implications of its ruling. It explained that allowing “fraud on the FDA” FCA theories in the absence of official FDA recognition of the alleged fraud would “turn the FCA into a tool with which a jury of six people could retroactively eliminate the value of FDA approval and effectively require that a product largely be withdrawn from the market even when the FDA itself sees no reason to do so.” 2016 WL 7422943 at *6. It also acknowledged that its ruling poses the “theoretical risk” that the government might seek to prevent a would-be relator from recovering under the FCA by filing its own suit after relator notified FDA and sought official recognition of the fraud. Id. The panel concluded, however, that such risk is small, and that deterring whistleblowers is generally counter to the government’s own interest.

The court quickly dispensed with relator’s three other theories of liability. It held that relator failed adequately to allege that FDA required physicians to attend defendants’ training programs and, further, that relator had failed to allege that any supposedly untrained users had actually submitted claims for reimbursement to the government, as required by Fed. R. Civ. P. 9(b) and First Circuit precedent. Regarding Axium, the panel held that relator had not plausibly alleged that every claim for Axium was false. The panel concluded that relator’s manufacturing and design defect allegations respectively established, at best, that only certain lots were defective and that later generations of the device improved upon the original design, which did not make the earlier generations defective.

Implications of the Court’s Decision

This case marks the first time that a federal court of appeals has held that “some official action by the FDA confirming that its approval was actually procured” by fraudulent representations is necessary in order for a “fraud on the FDA” FCA theory to be viable. Id. Not only will this holding likely be a significant impediment to FCA cases based on such theories in the First Circuit, but its reasoning may also convince other circuits to follow suit.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions